1-甲氧基-3-甲基-萘 | 828-84-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 1-甲氧基-3-甲基-萘
• 中文别名: 抗菌的LL-BM782(9CI)
• 英文名称: 1-methoxy-3-methylnaphthalene
• 英文别名: 1-Methoxy-3-methyl-naphthalin；1-Methoxy-3-methylnaphthalin
• CAS: 828-84-2
• 化学式: C₁₂H₁₂O
• 分子量: 172.227
• InChiKey: CTKKMNJQJKRSSA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-甲氧基-3-甲基-萘 在 三氯化铝 、 吡啶盐酸盐 作用下， 以 硝基苯 为溶剂， 生成 [3-Methyl-6-(2-methylene-butyryl)-naphthalen-1-yloxy]-acetic acid
  参考文献：
  名称：

  BE651724

  摘要：

  公开号：
• 作为产物：
  描述：

  3-甲基-1-萘酚 、 硫酸二甲酯 在 sodium hydroxide 作用下， 生成 1-甲氧基-3-甲基-萘
  参考文献：
  名称：

  Overeem,J.C.; van der Kerk,G.J.M., Recueil des Travaux Chimiques des Pays-Bas, 1964, vol. 83, p. 1005 - 1022

  摘要：

  DOI：

文献信息

• COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
  申请人：Li Hui

  公开号：US20100190770A1

  公开（公告）日：2010-07-29

  Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.

  公开了化合物I的结构，含有这些化合物的组合物，以及在治疗需要调节JAK途径或抑制JAK激酶，特别是JAK 2和JAK3的情况下使用这些化合物和组合物的方法。
• Compounds and Methods for Catalytic Directed ortho Substitution of Aromatic Amides and Esters
  申请人：Zhao Yigang

  公开号：US20120302752A1

  公开（公告）日：2012-11-29

  Methods are described for efficient and regioselective reactions that are Ru-catalyzed and either (i) amide-directed C—H, C—N, C—O activation/C—C bond forming reactions, (ii) ester-directed C—O and C—N activation/C—C bond forming reactions, or (iii) amide-directed C—O activation/hydrodemethoxylation reactions. All of these reactions of directed C—H, C—N, C—O activation/coupling reactions establish a catalytic base-free DoM-cross coupling process at non-cryogenic temperature. High regioselectivity, yields, operational simplicity, low cost, and convenient scale-up make these reactions suitable for industrial applications. Many previously unknown amide-substituted or ester-substituted aryl and heteroaryl compounds are presented with synthetic details also provided.

  描述了一种高效和区域选择性反应的方法，这些反应是以钌为催化剂的，可以是（i）酰胺导向的C—H、C—N、C—O活化/C—C键形成反应，（ii）酯导向的C—O和C—N活化/C—C键形成反应，或者（iii）酰胺导向的C—O活化/脱甲氧基反应。所有这些导向C—H、C—N、C—O活化/偶联反应在非低温下建立了一个无催化剂碱的DoM-交叉偶联过程。高区域选择性、产率、操作简便、低成本和便于放大规模使得这些反应适用于工业应用。还提供了许多以前未知的酰胺取代或酯取代的芳基和杂环芳基化合物，同时提供了合成细节。
• [EN] VEGFR TYROSINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE TYROSINE KINASE VEGFR
  申请人：SUZHOU VIVOTIDE BIOTECHNOLOGIES CO LTD

  公开号：WO2014183300A1

  公开（公告）日：2014-11-20

  Novel compounds, their prodrugs, and the pharmaceutically acceptable salts as pharmaceutical compositions containing such compounds useful in treating certain diseases modulated by the inhibition of vascular endothelial growth factors (VEGFs) receptor tyrosine kinases are provided. In particular, compounds and compositions and the methods for the prophylaxis, management and treatment of cancers through the inhibition of VEGF receptor tyrosine kinases are provided.

  提供了作为含有这些化合物的药物组合物的前药和药用盐，用于治疗受血管内皮生长因子（VEGFs）受体酪氨酸激酶抑制调节的特定疾病。具体提供了通过抑制VEGF受体酪氨酸激酶来预防、管理和治疗癌症的化合物、组合物和方法。
• INFLAMMATORY CYTOKINE RELEASE INHIBITOR
  申请人：MUTO Susumu

  公开号：US20090192122A2

  公开（公告）日：2009-07-30

  A medicament having inhibitory activity against NF-κB activation, which comprises a compound represented by the following general formula (I) or a pharmacologically acceptable salt as an active ingredient: wherein X represents a connecting group, A represents hydrogen atom or acetyl group, E represents an aryl group or a heteroaryl group, and ring X represents an arene or a heteroarene.

  一种具有抑制NF-κB激活活性的药物，其包括以下通式(I)所表示的化合物或其药理学上可接受的盐作为活性成分：其中X代表连接基，A代表氢原子或乙酰基，E代表芳基或杂芳基，环X代表芳烃或杂芳烃。
• ANTIALLERGIC AGENTS
  申请人：Muto Susumu

  公开号：US20080090779A1

  公开（公告）日：2008-04-17

  A medicament for the preventive and/or therapeutic treatment of allergic diseases and/or endometriosis and/or hysteromyoma which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.

  一种预防和/或治疗过敏性疾病和/或子宫内膜异位症和/或子宫肌瘤的药物，其包括以下通式（I）所表示的化合物或其药学上可接受的盐、水合物和溶剂化物作为活性成分，其中X表示连接基，其主链中原子数为2至5（该连接基可以被取代），A表示氢原子或乙酰基，E表示芳基或取代的杂芳基，环Z表示苯环，除了由公式-O-A表示的基团，该苯环还可以具有一个或多个取代基团，其中A的含义与上述定义相同，而由公式-X-E表示的基团中，每个X和E的含义也与上述定义相同，或者是一个杂环，除了由公式-O-A表示的基团，该杂环还可以具有一个或多个取代基团，其中A的含义与上述定义相同，而由公式-X-E表示的基团中，每个X和E的含义也与上述定义相同。